Non-alcoholic steatohepatitis (NASH) occurs when fat accumulates in the liver due to causes other than excessive alcohol consumption. It is a progressive liver disease characterised by inflammation and fibrosis, and has strong links to diabetes, obesity and cardiovascular diseases1. By 2030, the number of NASH patients is expected to increase by 60% and the number of liver deaths related to NASH by 178%2. Currently, the majority of people who have NASH remain undiagnosed3 due to the invasive nature of diagnostic procedures and there are no approved pharmacological treatments for the disease. Novo Nordisk is working on solutions to both of these challenges.
DISEASE EXPERIENCE EXPERT PANELS
At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.
“I’m excited about our pipeline! I believe we will bring effective medicines with high safety to market in the years to come – medicines that may change the lives of people with NASH.”
More than 80% of people with NASH are also living with obesity3
More than 40% of people with NASH have diabetes3
5–6% people are estimated to be affected by NASH3
We are always ready to build alliances to advance science and address unmet medical needs. Within NASH, we are looking for partners with expertise in novel modalities that address fibrosis and inflammation. To learn more about how we can work together, please visit our partnering pages.
Today, the diagnosis of NASH requires an invasive and often painful liver biopsy, and diagnosis rates are consequently low. To facilitate diagnosis and overcome treatment barriers, Novo Nordisk participates in international forums such as LITMUS, which support the identification of alternative, non-invasive means for diagnosing NASH as well as for monitoring progression or regression of the disease.
We are mobilising our expertise in metabolism and protein technology to discover and develop treatments for NASH. To support our aims, the cardiovascular and liver diseases research departments at our world-class research center in Måløv, Denmark, are expanding their teams of drug researchers. Visit our careers page to learn more.
To contribute to the
scientific community in our areas of expertise, we take pride in
publishing our scientists’ new findings. Visit the library to review
some of their recent work.